The primary objective of this trial is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein(a).
Кой може да участва
Inclusion Criteria:
* Age 18 to ≤ 85 years
* Lp(a) ≥ 200 nmol/L during screening
* History of ASCVD as evidenced by history of either:
* Myocardial infarction (presumed type 1 event due to plaque rupture/erosion) and/or
* Coronary revascularization with percutaneous coronary intervention AND at least 1 additional risk factor.
Exclusion Criteria:
* Severe renal dysfunction
* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 3 x upper limit of normal (ULN), or total bilirubin (TBL) \> 2 x ULN during screening
* History of hemorrhagic stroke
* History of major bleeding disorder
* Planned cardiac surgery or arterial revascularization
* Severe heart failure
* Current, recent, or planned lipoprotein apheresis
* Previously received ribonucleic acid therapy specifically targeting Lp(a)
Места на провеждане
31
Argentina (1)
Instituto de Investigaciones Clinicas Bahia Blanca
Bahía Blanca , Buenos Aires
Австралия (1)
Canberra Hospital
Garran , Australian Capital Territory
Белгия (1)
Algemeen Stedelijk Ziekenhuis Aalst
Aalst
Бразилия (1)
Hospital Universitario Walter Cantidio
Fortaleza , Ceará
България (1)
Multiprofile Hospital for Active Treatment Puls AD
Blagoevgrad
Канада (1)
ARC Biosystems Incorporated
Vancouver , British Columbia
Китай (1)
Peking University Third Hospital
Beijing , Beijing Municipality
Чехия (1)
Jessenia as, Nemocnice Beroun
Beroun
Дания (1)
Aalborg Universitetshospital
Aalborg
Estonia (1)
Innomedica
Tallinn
Финландия (1)
Helsinki University Central Hospital
Helsinki
Франция (1)
Centre Hospitalier Regional Universitaire de Besancon, Hopital Jean Minjoz
БГ
EN